|
|
|||||||||
|
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail. Appendix B TREATMENT OPTIONS FOR PET BIRDS WITH AVIAN CHLAMYDIOSISThe following methods are established as effective treatments for avian chlamydiosis (AC). All birds with AC should be treated for 45 days, except as noted below: Medicated Feed Medicated feed should be the only food provided to the birds during the entire treatment. Birds' acceptance of medicated feed is variable. Thus, food consumption should be monitored. Acceptance may be enhanced by first adapting the birds to a similar, nonmedicated diet. Treatment begins when the birds accept the medicated feed as the sole food in their diet. The following options are available:
The National Association of State Public Health Veterinarians (NASPHV) can provide a list of companies that sell medicated feed. Address requests to NASPHV, RSA Tower, Suite 1310, P.O. Box 303017, Montgomery, AL 36130-3017. Oral or Parenteral Treatments Three treatments available include oral doxycycline, injectable doxycycline, and injectable oxytetracycline. Oral Doxycycline Doxycycline is the drug of choice for oral treatment; either the monohydrate or calcium-syrup formulations can be used. Based on nonpeer-reviewed studies, dosage recommendations are as follows: 40-50 mg/kg body weight by mouth once a day for cockatiels, Senegal parrots, and blue-fronted and orange-winged Amazon parrots; and 25 mg/kg body weight by mouth once a day for African grey parrots, Goffin's cockatoos, blue and gold macaws, and green-winged macaws. Precise dosages cannot be extrapolated for untested species; however, 25-30 mg/kg body weight administered by mouth once a day is the recommended starting dosage for cockatoos and macaws, and 25-50 mg/kg by mouth once a day is recommended for other psittacine species. If the bird regurgitates the drug, another treatment method should be used. Injectable Doxycycline Intramuscular (IM) injection into the pectoral muscle is often the easiest method of treatment, but not all injectable-doxycycline formulations are suitable for IM injection. All available formulations can cause irritation at the injection site. The VibrovenosTM formulation (Pfizer Laboratories, London, Ontario, Canada) is available in Canada and Europe and is effective if administered at doses of 75-100 mg/kg body weight IM every 5-7 days for the first 4 weeks and subsequently every 5 days for the duration of treatment. Anecdotal reports indicate that pharmacist-compounded, injectable-doxycycline products have been used successfully in the United States. However, data are insufficient to determine precise dosage schedules. The injectable-hyclate formulation labeled for intravenous use in humans in the United States is not suitable for IM use in birds because severe tissue reactions will occur at the site of injection. Injectable Oxytetracycline Limited information exists for the use of an injectable, long-acting oxytetracycline product (LA-200TM; Pfizer Laboratories, Exton, Pennsylvania). Current dosage recommendations are as follows: subcutaneous injection of 75 mg/kg body weight every 3 days in Goffin's cockatoos, blue-fronted and orange-winged Amazon parrots, and blue and gold macaws. This dosage may be suitable for but has not been tested on other species. This product causes irritation at the site of injection and is best used to initiate treatment in ill birds or those that are reluctant to eat. After stabilization with oxytetracycline treatment, the birds should be switched to another form of treatment to reduce the muscle irritation that is caused by repeated oxytetracycline injection. Experimental Methods Treatment protocols using fluoroquinolones, late-generation macrolides, pharmacist-compounded injectable doxycycline, and doxycycline-medicated feed are under investigation. Information about these treatment protocols may be available in the scientific literature or from avian veterinary specialists.
Disclaimer All MMWR HTML versions of articles are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the electronic PDF version and/or the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices. **Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.Page converted: 10/05/98 |
|||||||||
This page last reviewed 5/2/01
|